Symbols / NVO $39.22 +1.66%
NVO Chart
About
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 174.91B |
| Enterprise Value | 275.45B | Income | 102.43B | Sales | 309.06B |
| Book/sh | 6.73 | Cash/sh | 6.07 | Dividend Yield | 4.82% |
| Payout | 50.42% | Employees | 68794 | IPO | — |
| P/E | 11.05 | Forward P/E | 11.76 | PEG | — |
| P/S | 0.57 | P/B | 5.83 | P/C | — |
| EV/EBITDA | 1.80 | EV/Sales | 0.89 | Quick Ratio | 0.54 |
| Current Ratio | 0.80 | Debt/Eq | 67.49 | LT Debt/Eq | — |
| EPS (ttm) | 3.55 | EPS next Y | 3.33 | EPS Growth | -4.70% |
| Revenue Growth | -7.60% | Earnings | 2026-05-06 | ROA | 17.43% |
| ROE | 60.70% | ROIC | — | Gross Margin | 82.41% |
| Oper. Margin | 44.53% | Profit Margin | 33.14% | Shs Outstand | 3.37B |
| Shs Float | 3.19B | Short Float | 0.89% | Short Ratio | 0.99 |
| Short Interest | — | 52W High | 82.57 | 52W Low | 35.85 |
| Beta | 0.27 | Avg Volume | 24.50M | Volume | 2.10M |
| Target Price | $47.44 | Recom | Buy | Prev Close | $38.58 |
| Price | $39.22 | Change | 1.66% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$47.35
Mean price target
2. Current target
$38.58
Latest analyst target
3. DCF / Fair value
$2.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$38.58
Low
$39.75
High
$63.45
Mean
$47.35
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | down | Goldman Sachs | Buy → Neutral | $41 |
| 2026-02-24 | down | JP Morgan | Overweight → Neutral | — |
| 2026-01-09 | init | CICC | — → Outperform | $74 |
| 2025-12-08 | down | Argus Research | Buy → Hold | — |
| 2025-11-28 | main | Goldman Sachs | Buy → Buy | $54 |
| 2025-11-25 | main | BMO Capital | Market Perform → Market Perform | $46 |
| 2025-11-24 | down | HSBC | Buy → Hold | — |
| 2025-10-14 | main | BMO Capital | Market Perform → Market Perform | $55 |
| 2025-10-02 | up | HSBC | Hold → Buy | $70 |
| 2025-09-29 | down | Morgan Stanley | Equal-Weight → Underweight | $47 |
| 2025-09-17 | up | Berenberg | Hold → Buy | — |
| 2025-08-19 | main | TD Cowen | Buy → Buy | $70 |
| 2025-08-05 | down | UBS | Buy → Neutral | — |
| 2025-07-31 | down | HSBC | Buy → Hold | — |
| 2025-07-30 | down | Barclays | Overweight → Equal-Weight | — |
| 2025-06-18 | reit | TD Cowen | Buy → Buy | $105 |
| 2025-04-17 | down | BMO Capital | Outperform → Market Perform | $64 |
| 2025-01-08 | up | UBS | Sell → Buy | — |
| 2024-12-23 | main | BMO Capital | Outperform → Outperform | $105 |
| 2024-11-06 | reit | Cantor Fitzgerald | Overweight → Overweight | $160 |
News
RSS: Latest NVO news- Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade) (NYSE:NVO) - Seeking Alpha Fri, 13 Mar 2026 20
- Bank of America Corp DE Cuts Stock Position in Novo Nordisk A/S $NVO - MarketBeat ue, 17 Mar 2026 07
- NVO Stock: Should You Buy The Dip? - Forbes ue, 24 Feb 2026 08
- Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know - Insider Monkey ue, 17 Mar 2026 10
- Novo Nordisk Stock Forecast | 2026 Sales Guidance Cut - Capital.com Fri, 06 Mar 2026 08
- Does This Deal Make Novo Nordisk Stock a Buy? - The Motley Fool hu, 12 Mar 2026 15
- Assessing Novo Nordisk (NYSE:NVO) After A 47% One-Year Share Price Pullback - simplywall.st hu, 12 Mar 2026 09
- Novo Nordisk: Buy Hand Over Fist While Others Panic (NYSE:NVO) - Seeking Alpha ue, 17 Mar 2026 12
- Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya - Yahoo Finance Sun, 01 Mar 2026 08
- Flow Traders U.S. LLC Has $2.28 Million Stock Position in Novo Nordisk A/S $NVO - MarketBeat ue, 17 Mar 2026 09
- Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance hu, 12 Mar 2026 21
- Novo Nordisk Stock Forecast | Guidance Cut and Buyback - Capital.com Fri, 13 Mar 2026 08
- Novo Nordisk’s stock slump cuts assets of largest shareholder by a third (NVO:NYSE) - Seeking Alpha hu, 12 Mar 2026 07
- Novo Nordisk A/S (NYSE:NVO) Trading 1.6% Higher - What's Next? - MarketBeat Mon, 16 Mar 2026 21
- Novo's Quiet Comeback Begins (NYSE:NVO) - Seeking Alpha Mon, 09 Mar 2026 13
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.31B | -214.25M | 339.49M | -1.03B |
| TaxRateForCalcs | 0.22 | 0.21 | 0.20 | 0.20 |
| NormalizedEBITDA | 150.65B | 148.98B | 112.94B | 82.04B |
| TotalUnusualItems | 6.08B | -1.04B | 1.69B | -5.24B |
| TotalUnusualItemsExcludingGoodwill | 6.08B | -1.04B | 1.69B | -5.24B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 102.43B | 100.99B | 83.68B | 55.52B |
| ReconciledDepreciation | 21.98B | 19.11B | 9.41B | 7.36B |
| ReconciledCostOfRevenue | 58.79B | 44.52B | 35.77B | 28.45B |
| EBITDA | 156.73B | 147.94B | 114.63B | 76.80B |
| EBIT | 134.75B | 128.83B | 105.22B | 69.44B |
| NetInterestIncome | -3.18B | -91.00M | 330.00M | -320.00M |
| InterestExpense | 4.21B | 1.64B | 542.00M | 378.00M |
| InterestIncome | 1.27B | 1.84B | 1.07B | 239.00M |
| NormalizedIncome | 97.66B | 101.81B | 82.33B | 59.74B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 102.43B | 100.99B | 83.68B | 55.52B |
| TotalExpenses | 181.41B | 162.06B | 129.69B | 102.14B |
| TotalOperatingIncomeAsReported | 127.66B | 128.34B | 102.57B | 74.81B |
| DilutedAverageShares | 4.45B | 4.46B | 4.49B | 4.54B |
| BasicAverageShares | 4.44B | 4.45B | 4.48B | 4.53B |
| DilutedEPS | 23.03 | 22.63 | 18.62 | 12.22 |
| BasicEPS | 23.06 | 22.67 | 18.67 | 12.26 |
| DilutedNIAvailtoComStockholders | 102.43B | 100.99B | 83.68B | 55.52B |
| NetIncomeCommonStockholders | 102.43B | 100.99B | 83.68B | 55.52B |
| NetIncome | 102.43B | 100.99B | 83.68B | 55.52B |
| NetIncomeIncludingNoncontrollingInterests | 102.43B | 100.99B | 83.68B | 55.52B |
| NetIncomeContinuousOperations | 102.43B | 100.99B | 83.68B | 55.52B |
| TaxProvision | 28.11B | 26.20B | 20.99B | 13.54B |
| PretaxIncome | 130.54B | 127.19B | 104.67B | 69.06B |
| OtherIncomeExpense | 6.06B | -1.06B | 1.77B | -5.43B |
| EarningsFromEquityInterest | -17.00M | -17.00M | 81.00M | -189.00M |
| GainOnSaleOfSecurity | 6.08B | -1.04B | 1.69B | -5.24B |
| NetNonOperatingInterestIncomeExpense | -3.18B | -91.00M | 330.00M | -320.00M |
| TotalOtherFinanceCost | 241.00M | 289.00M | 197.00M | 181.00M |
| InterestExpenseNonOperating | 4.21B | 1.64B | 542.00M | 378.00M |
| InterestIncomeNonOperating | 1.27B | 1.84B | 1.07B | 239.00M |
| OperatingIncome | 127.66B | 128.34B | 102.57B | 74.81B |
| OperatingExpense | 122.62B | 117.54B | 93.92B | 73.70B |
| OtherOperatingExpenses | 300.00M | 2.10B | -119.00M | -1.03B |
| ResearchAndDevelopment | 52.04B | 48.06B | 32.44B | 24.05B |
| SellingGeneralAndAdministration | 70.28B | 67.38B | 61.60B | 50.68B |
| SellingAndMarketingExpense | 64.31B | 62.10B | 56.74B | 46.22B |
| GeneralAndAdministrativeExpense | 5.97B | 5.28B | 4.86B | 4.47B |
| OtherGandA | 5.97B | 5.28B | 4.86B | 4.47B |
| GrossProfit | 250.28B | 245.88B | 196.50B | 148.51B |
| CostOfRevenue | 58.79B | 44.52B | 35.77B | 28.45B |
| TotalRevenue | 309.06B | 290.40B | 232.26B | 176.95B |
| OperatingRevenue | 729.42B | 680.56B | 608.64B | 455.69B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 21.52M | 23.66M | 51.71M | 60.20M |
| OrdinarySharesNumber | 4.44B | 4.44B | 4.46B | 4.50B |
| ShareIssued | 4.46B | 4.46B | 4.51B | 4.56B |
| NetDebt | 95.92B | 80.37B | 6.89B | 8.60B |
| TotalDebt | 130.96B | 102.79B | 27.01B | 25.78B |
| TangibleBookValue | 63.99B | 32.66B | 46.16B | 32.55B |
| InvestedCapital | 316.43B | 239.51B | 127.84B | 104.74B |
| WorkingCapital | -43.21B | -55.83B | -30.01B | -12.75B |
| NetTangibleAssets | 63.99B | 32.66B | 46.16B | 32.55B |
| CapitalLeaseObligations | 8.57B | 6.77B | 5.73B | 4.53B |
| CommonStockEquity | 194.05B | 143.49B | 106.56B | 83.49B |
| TotalCapitalization | 305.75B | 227.73B | 122.54B | 104.26B |
| TotalEquityGrossMinorityInterest | 194.05B | 143.49B | 106.56B | 83.49B |
| StockholdersEquity | 194.05B | 143.49B | 106.56B | 83.49B |
| GainsLossesNotAffectingRetainedEarnings | -1.70B | -1.41B | 1.28B | 2.45B |
| OtherEquityAdjustments | -1.70B | -1.41B | 1.28B | 2.45B |
| TreasuryStock | 2.00M | 2.00M | 5.00M | 6.00M |
| RetainedEarnings | 195.30B | 144.45B | 104.84B | 80.59B |
| CapitalStock | 446.00M | 446.00M | 451.00M | 456.00M |
| CommonStock | 446.00M | 446.00M | 451.00M | 456.00M |
| TotalLiabilitiesNetMinorityInterest | 348.86B | 322.14B | 207.93B | 157.77B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 133.19B | 104.53B | 38.27B | 36.83B |
| OtherNonCurrentLiabilities | 23.00M | 189.00M | 100.00M | 360.00M |
| EmployeeBenefits | 861.00M | 903.00M | 742.00M | 762.00M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 861.00M | 903.00M | 742.00M | 762.00M |
| TradeandOtherPayablesNonCurrent | 1.05B | 1.46B | 189.00M | 100.00M |
| NonCurrentDeferredLiabilities | 6.61B | 5.51B | 10.16B | 7.06B |
| NonCurrentDeferredTaxesLiabilities | 6.61B | 5.51B | 10.16B | 7.06B |
| LongTermDebtAndCapitalLeaseObligation | 118.94B | 89.67B | 20.53B | 24.32B |
| LongTermCapitalLeaseObligation | 7.24B | 5.43B | 4.55B | 3.54B |
| LongTermDebt | 111.70B | 84.25B | 15.98B | 20.77B |
| LongTermProvisions | 5.73B | 6.98B | 6.65B | 4.59B |
| CurrentLiabilities | 215.66B | 217.61B | 169.66B | 120.94B |
| OtherCurrentLiabilities | 41.75B | 42.90B | 29.98B | 26.51B |
| CurrentDebtAndCapitalLeaseObligation | 12.02B | 13.11B | 6.48B | 1.47B |
| CurrentCapitalLeaseObligation | 1.34B | 1.34B | 1.17B | 986.00M |
| CurrentDebt | 10.68B | 11.78B | 5.30B | 480.00M |
| OtherCurrentBorrowings | 9.75B | 5.98B | 4.85B | 12.50B |
| LineOfCredit | 183.00M | 449.00M | 456.00M | 480.00M |
| CommercialPaper | 745.00M | 5.34B | 0.00 | |
| CurrentNotesPayable | 0.00 | 0.00 | ||
| CurrentProvisions | 374.00M | 289.00M | 100.48B | 70.29B |
| PayablesAndAccruedExpenses | 161.52B | 161.31B | 32.72B | 22.68B |
| Payables | 161.52B | 161.31B | 32.72B | 22.68B |
| TotalTaxPayable | 8.42B | 9.72B | 7.12B | 7.09B |
| AccountsPayable | 153.11B | 151.59B | 25.61B | 15.59B |
| TotalAssets | 542.90B | 465.63B | 314.49B | 241.26B |
| TotalNonCurrentAssets | 370.45B | 303.84B | 174.84B | 133.06B |
| NonCurrentDeferredAssets | 23.65B | 24.65B | 20.38B | 13.90B |
| NonCurrentDeferredTaxesAssets | 23.65B | 24.65B | 20.38B | 13.90B |
| NonCurrentAccountsReceivable | 5.86B | 4.02B | 1.43B | 206.00M |
| InvestmentsAndAdvances | 2.51B | 2.68B | 1.66B | 1.34B |
| InvestmentinFinancialAssets | 2.14B | 2.28B | 1.25B | 1.02B |
| AvailableForSaleSecurities | 2.14B | 2.28B | 1.25B | 1.02B |
| LongTermEquityInvestment | 366.00M | 400.00M | 410.00M | 327.00M |
| InvestmentsinAssociatesatCost | 366.00M | 400.00M | 410.00M | 327.00M |
| GoodwillAndOtherIntangibleAssets | 130.05B | 110.82B | 60.41B | 50.94B |
| OtherIntangibleAssets | 110.21B | 90.80B | 55.94B | 46.32B |
| Goodwill | 19.84B | 20.02B | 4.46B | 4.62B |
| NetPPE | 208.38B | 161.68B | 90.96B | 66.67B |
| AccumulatedDepreciation | -58.94B | -52.40B | -47.62B | -44.76B |
| GrossPPE | 267.31B | 214.08B | 138.58B | 111.43B |
| ConstructionInProgress | 130.62B | 85.50B | 39.66B | 22.36B |
| OtherProperties | 11.11B | 10.17B | 8.98B | 8.11B |
| MachineryFurnitureEquipment | 60.02B | 57.04B | 40.95B | 37.55B |
| Properties | 65.56B | 61.37B | 48.99B | 43.40B |
| CurrentAssets | 172.45B | 161.79B | 139.65B | 108.19B |
| HedgingAssetsCurrent | 6.68B | 6.33B | 2.34B | 2.73B |
| Inventory | 49.62B | 40.85B | 31.81B | 24.39B |
| InventoriesAdjustmentsAllowances | -5.66B | -3.73B | -2.51B | -1.72B |
| FinishedGoods | 11.99B | 8.87B | 7.22B | 6.04B |
| WorkInProcess | 25.86B | 22.34B | 17.60B | 13.67B |
| RawMaterials | 17.44B | 13.37B | 9.50B | 6.39B |
| Receivables | 89.19B | 88.31B | 75.26B | 57.51B |
| OtherReceivables | 13.48B | 13.50B | 8.07B | 6.00B |
| TaxesReceivable | 4.85B | 2.85B | 2.42B | 940.00M |
| AccountsReceivable | 70.86B | 71.95B | 64.77B | 50.56B |
| AllowanceForDoubtfulAccountsReceivable | -1.99B | -2.13B | -1.79B | -1.52B |
| GrossAccountsReceivable | 72.84B | 74.08B | 66.56B | 52.08B |
| CashCashEquivalentsAndShortTermInvestments | 26.96B | 26.31B | 30.23B | 23.57B |
| OtherShortTermInvestments | 498.00M | 10.65B | 15.84B | 10.92B |
| CashAndCashEquivalents | 26.46B | 15.65B | 14.39B | 12.65B |
| CashFinancial | 26.46B | 15.65B | 14.39B | 12.65B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 28.99B | 69.66B | 70.01B | 64.13B |
| RepurchaseOfCapitalStock | -1.39B | -20.18B | -29.92B | -24.09B |
| RepaymentOfDebt | -79.19B | -6.33B | -1.47B | -13.62B |
| IssuanceOfDebt | 103.93B | 79.39B | 0.00 | 11.21B |
| CapitalExpenditure | -90.11B | -51.31B | -38.90B | -14.75B |
| EndCashPosition | 26.46B | 15.65B | 14.39B | 12.65B |
| BeginningCashPosition | 15.65B | 14.39B | 12.65B | 10.72B |
| EffectOfExchangeRateChanges | -727.00M | 455.00M | -119.00M | -238.00M |
| ChangesInCash | 11.54B | 808.00M | 1.86B | 2.17B |
| FinancingCashFlow | -28.41B | 8.73B | -63.16B | -51.80B |
| CashFlowFromContinuingFinancingActivities | -28.41B | 8.73B | -63.16B | -51.80B |
| CashDividendsPaid | -51.76B | -44.14B | -31.77B | -25.30B |
| NetCommonStockIssuance | -1.39B | -20.18B | -29.92B | -24.09B |
| CommonStockPayments | -1.39B | -20.18B | -29.92B | -24.09B |
| NetIssuancePaymentsOfDebt | 24.74B | 73.06B | -1.47B | -2.41B |
| NetLongTermDebtIssuance | 24.74B | 73.06B | -1.47B | -2.41B |
| LongTermDebtPayments | -79.19B | -6.33B | -1.47B | -13.62B |
| LongTermDebtIssuance | 103.93B | 79.39B | 0.00 | 11.21B |
| InvestingCashFlow | -79.16B | -128.90B | -43.89B | -24.92B |
| CashFlowFromContinuingInvestingActivities | -79.16B | -128.90B | -43.89B | -24.92B |
| DividendsReceivedCFI | 0.00 | 0.00 | 4.00M | |
| NetInvestmentPurchaseAndSale | 9.95B | 4.58B | -5.00B | -3.09B |
| SaleOfInvestment | 10.67B | 24.39B | 8.29B | 6.64B |
| PurchaseOfInvestment | -723.00M | -19.81B | -13.29B | -9.73B |
| NetBusinessPurchaseAndSale | 1.00B | -82.16B | 0.00 | -7.08B |
| SaleOfBusiness | 1.00B | 0.00 | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -82.16B | 0.00 | -7.08B |
| NetIntangiblesPurchaseAndSale | -29.97B | -4.14B | -13.09B | -2.61B |
| PurchaseOfIntangibles | -29.97B | -4.14B | -13.09B | -2.61B |
| NetPPEPurchaseAndSale | -60.14B | -47.16B | -25.81B | -12.15B |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -60.14B | -47.16B | -25.81B | -12.15B |
| OperatingCashFlow | 119.10B | 120.97B | 108.91B | 78.89B |
| CashFlowFromContinuingOperatingActivities | 119.10B | 120.97B | 108.91B | 78.89B |
| TaxesRefundPaid | -32.01B | -29.64B | -25.90B | -14.52B |
| InterestReceivedCFO | 1.40B | 1.88B | 1.07B | 276.00M |
| InterestPaidCFO | -3.42B | -612.00M | -491.00M | -272.00M |
| ChangeInWorkingCapital | 3.74B | 2.59B | 19.71B | -5.54B |
| ChangeInOtherWorkingCapital | 2.51B | -1.24B | 1.16B | 74.00M |
| ChangeInOtherCurrentLiabilities | 9.12B | 5.10B | 3.75B | 2.60B |
| ChangeInPayablesAndAccruedExpense | -280.00M | 7.59B | 5.15B | 3.14B |
| ChangeInPayable | -280.00M | 7.59B | 5.15B | 3.14B |
| ChangeInAccountPayable | 3.24B | 10.02B | 6.72B | 3.15B |
| ChangeInInventory | -9.04B | -7.42B | -4.77B | -1.08B |
| ChangeInReceivables | -14.31B | -16.27B | -10.82B | -13.79B |
| ChangesInAccountReceivables | -7.18B | -14.21B | -9.92B | -12.91B |
| OtherNonCashItems | -3.12B | 445.00M | 424.00M | 2.37B |
| StockBasedCompensation | 2.29B | 2.15B | 1.54B | 1.04B |
| ProvisionandWriteOffofAssets | 21.03B | 32.23B | 18.46B | |
| AssetImpairmentCharge | 10.56B | 809.00M | ||
| DeferredTax | 28.11B | 26.20B | 20.99B | 13.54B |
| DeferredIncomeTax | 28.11B | 26.20B | 20.99B | 13.54B |
| DepreciationAmortizationDepletion | 21.98B | 19.11B | 9.41B | 7.36B |
| DepreciationAndAmortization | 21.98B | 19.11B | 9.41B | 7.36B |
| AmortizationCashFlow | 2.51B | 1.60B | ||
| AmortizationOfIntangibles | 2.51B | 1.60B | ||
| Depreciation | 21.98B | 19.11B | 9.41B | 7.36B |
| OperatingGainsLosses | -11.03B | 32.27B | 138.00M | 16.27B |
| PensionAndEmployeeBenefitExpense | -119.00M | 32.24B | 615.00M | 16.58B |
| EarningsLossesFromEquityInvestments | 17.00M | -81.00M | 189.00M | 24.00M |
| GainLossOnInvestmentSecurities | -5.08B | 106.00M | 2.57B | -340.00M |
| NetForeignCurrencyExchangeGainLoss | -5.85B | 2.28B | -3.24B | |
| NetIncomeFromContinuingOperations | 102.43B | 100.99B | 83.68B | 55.52B |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NVO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|